Latest News and Press Releases

Des données de dernière minute sur Dupixent® (dupilumab) présentées au congrès de l’ERS 2022 montrent un profil de sécurité et d’efficacité homogène pendant une durée pouvant atteindre deux ans, chez...

 Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma Results from the...

XenpozymeTM (olipudase alfa-rpcp) approuvé par la FDA – premier médicament indiqué expressément pour le traitement des manifestations non neurologiques du déficit en sphingomyélinase acide  Paris, le...

XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)   Paris, August 31, 2022. The U.S. Food and Drug Administration (FDA) has...

IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR)...

LOS GATOS, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- TidalScale, the company leading the Software-Defined Server revolution, today announced updates to its fourth generation Software-Defined Server...

La FDA accorde un examen prioritaire à l’efanesoctocog alpha pour le traitement de l’hémophilie ALa décision de la FDA concernant l’efanesoctocog alpha, un facteur VIII de remplacement...

FDA grants priority review to efanesoctocog alfa for people with hemophilia AThe FDA decision date for efanesoctocog alfa, an investigational factor VIII therapy, is set for February 28, 2023Priority...

MOUNTAIN VIEW, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- StarTree, Inc. today announced $47 million in Series B funding to accelerate product development, expand sales and marketing, and continue to...

DUBLIN, Ireland, Aug. 26, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “Business Management Consulting Services Market Size, Share, Growth Analysis Report By...